8
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Additives for vaccine storage to improve thermal stability of adenoviruses from hours to months

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Up to 80% of the cost of vaccination programmes is due to the cold chain problem (that is, keeping vaccines cold). Inexpensive, biocompatible additives to slow down the degradation of virus particles would address the problem. Here we propose and characterize additives that, already at very low concentrations, improve the storage time of adenovirus type 5. Anionic gold nanoparticles (10 −8–10 −6 M) or polyethylene glycol (PEG, molecular weight ∼8,000 Da, 10 −7–10 −4 M) increase the half-life of a green fluorescent protein expressing adenovirus from ∼48 h to 21 days at 37 °C (from 7 to >30 days at room temperature). They replicate the known stabilizing effect of sucrose, but at several orders of magnitude lower concentrations. PEG and sucrose maintained immunogenicity in vivo for viruses stored for 10 days at 37 °C. To achieve rational design of viral-vaccine stabilizers, our approach is aided by simplified quantitative models based on a single rate-limiting step.

          Abstract

          Keeping viral vaccines cold from the manufacturers to patients is problematic and costly. Here, Krol and others show additives that can significantly improve at very low concentrations the storage of adenovirus type 5 at ambient and elevated temperature.

          Related collections

          Most cited references41

          • Record: found
          • Abstract: found
          • Article: not found

          Surface-structure-regulated cell-membrane penetration by monolayer-protected nanoparticles.

          Nanoscale objects are typically internalized by cells into membrane-bounded endosomes and fail to access the cytosolic cell machinery. Whereas some biomacromolecules may penetrate or fuse with cell membranes without overt membrane disruption, no synthetic material of comparable size has shown this property yet. Cationic nano-objects pass through cell membranes by generating transient holes, a process associated with cytotoxicity. Studies aimed at generating cell-penetrating nanomaterials have focused on the effect of size, shape and composition. Here, we compare membrane penetration by two nanoparticle 'isomers' with similar composition (same hydrophobic content), one coated with subnanometre striations of alternating anionic and hydrophobic groups, and the other coated with the same moieties but in a random distribution. We show that the former particles penetrate the plasma membrane without bilayer disruption, whereas the latter are mostly trapped in endosomes. Our results offer a paradigm for analysing the fundamental problem of cell-membrane-penetrating bio- and macro-molecules.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Adenoviruses as vaccine vectors

            Adenoviruses have transitioned from tools for gene replacement therapy to bona fide vaccine delivery vehicles. They are attractive vaccine vectors as they induce both innate and adaptive immune responses in mammalian hosts. Currently, adenovirus vectors are being tested as subunit vaccine systems for numerous infectious agents ranging from malaria to HIV-1. Additionally, they are being explored as vaccines against a multitude of tumor-associated antigens. In this review we describe the molecular biology of adenoviruses as well as ways the adenovirus vectors can be manipulated to enhance their efficacy as vaccine carriers. We describe methods of evaluating immune responses to transgene products expressed by adenoviral vectors and discuss data on adenoviral vaccines to a selected number of pathogens. Last, we comment on the limitations of using human adenoviral vectors and provide alternatives to circumvent these problems. This field is growing at an exciting and rapid pace, thus we have limited our scope to the use of adenoviral vectors as vaccines against viral pathogens.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity.

              Recent studies of human immunodeficiency virus type 1 (HIV-1) infection in humans and of simian immunodeficiency virus (SIV) in rhesus monkeys have shown that resolution of the acute viral infection and control of the subsequent persistent infection are mediated by the antiviral cellular immune response. We comparatively assessed several vaccine vector delivery systems-three formulations of a plasmid DNA vector, the modified vaccinia Ankara (MVA) virus, and a replication incompetent adenovirus type 5 (Ad5) vector-expressing the SIV gag protein for their ability to elicit such immune responses in monkeys. The vaccines were tested either as a single modality or in combined modality regimens. Here we show that the most effective responses were elicited by a replication-incompetent Ad5 vector, used either alone or as a booster inoculation after priming with a DNA vector. After challenge with a pathogenic HIV-SIV hybrid virus (SHIV), the animals immunized with Ad5 vector exhibited the most pronounced attenuation of the virus infection. The replication-defective adenovirus is a promising vaccine vector for development of an HIV-1 vaccine.
                Bookmark

                Author and article information

                Journal
                Nat Commun
                Nat Commun
                Nature Communications
                Nature Publishing Group
                2041-1723
                30 November 2016
                2016
                : 7
                : 13520
                Affiliations
                [1 ]European School of Molecular Medicine (SEMM) , IFOM-IEO-Campus, via Adamello 16, Milan 20139, Italy
                [2 ]Università degli Studi di Milano , Milan 20122, Italy
                [3 ]Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta , IFOM-IEO-campus, via Adamello 16, Milan 20139, Italy
                [4 ]IFOM—FIRC Institute of Molecular Oncology, IFOM-IEO-campus, via Adamello 16, Milan 20139, Italy
                [5 ]Instituut-Lorentz for theoretical physics, Leiden University , 271, Niels Bohrweg 2, NL 2333 CA Leiden, The Netherlands
                [6 ]Fondazione CEN—European Centre for Nanomedicine , Piazza Leonardo da Vinci, 32, 20133 Milan, Italy
                [7 ]Laboratory of Molecular Virology and Antiviral Research, Department of Clinical and Biological Sciences, University of Turin, S. Luigi Gonzaga Hospital , Regione Gonzole 10, 10043 Orbassano, Italy
                [8 ]Vaccine & Gene Therapy Institute, Oregon Health & Science University , 505 NW 185th Avenue, Beaverton, Oregon 97006, USA
                [9 ]Institute of Materials and Interfaculty Bioengineering Institute, École polytechnique fédérale de Lausanne , STI IMX SUNMIL MXG 030, Station 12, CH-1015 Lausanne, Switzerland
                [10 ]Department of Biological and Environmental Science/Nanoscience Center, University of Jyväskyla , Survontie 9, 40500 Jyväskyla, Finland
                [11 ]Laboratory of Translational Nanotechnology, I.R.C.C.S. Istituto Tumori Giovanni Paolo II , viale Orazio, Flacco 65, Bari 70124, Italy
                [13 ]; ; ;
                Author notes
                [*]

                These authors contributed equally to this work

                [†]

                Present address: NorthWest Centre of Advanced Drug Delivery (NoWCADD), Division of Pharmacy & Optometry, School of Health Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, M13 9PT, UK

                [‡]

                Present address: Soft Matter Nanotechnology Group, CIC biomaGUNE, 182 C, 20009, San Sebastián, Guipúzcoa, Spain

                [§]

                Present address: Institute of Materials and Interfaculty Bioengineering Institute, Ecole polytechnique federale de Lausanne, STI IMX SUNMIL MXG 030, Station 12, CH-1015 Lausanne, Switzerland.

                [∥]

                Present address: University of California, Davis Dept. of Biochemistry and Molecular Medicine 2700 Stockton Blvd, Rm 2103 Sacramento, California 95817, USA.

                Author information
                http://orcid.org/0000-0001-8193-1664
                http://orcid.org/0000-0003-4635-6080
                Article
                ncomms13520
                10.1038/ncomms13520
                5141364
                27901019
                bd40c5f1-1c24-426b-99b4-41e391a1b1c3
                Copyright © 2016, The Author(s)

                This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

                History
                : 26 January 2016
                : 12 October 2016
                Categories
                Article

                Uncategorized
                Uncategorized

                Comments

                Comment on this article